# Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial

> **NCT02448550** · PHASE3 · TERMINATED · sponsor: **Kaiser Permanente** · enrollment: 250 (actual)

## Conditions studied

- Percutaneous Coronary Intervention

## Interventions

- **DRUG:** Bivalirudin
- **DRUG:** Unfractionated heparin

## Key facts

- **NCT ID:** NCT02448550
- **Lead sponsor:** Kaiser Permanente
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2016-05-06
- **Final completion:** 2016-06-16
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2018-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02448550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02448550, "Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02448550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*